Private Portfolio Partners LLC Acquires 17,907 Shares of Pfizer Inc. (NYSE:PFE)

Private Portfolio Partners LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 57.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,873 shares of the biopharmaceutical company's stock after acquiring an additional 17,907 shares during the period. Private Portfolio Partners LLC's holdings in Pfizer were worth $1,297,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Norges Bank purchased a new position in shares of Pfizer in the 4th quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $274,694,000. Massachusetts Financial Services Co. MA boosted its stake in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, Fisher Asset Management LLC increased its position in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock worth $295,760,000 after buying an additional 4,938,209 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 1.6 %

NYSE:PFE traded down $0.41 on Thursday, hitting $24.30. 53,412,700 shares of the stock were exchanged, compared to its average volume of 39,300,470. The stock has a market capitalization of $137.79 billion, a price-to-earnings ratio of 17.23, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52 week low of $24.26 and a 52 week high of $31.54. The company's 50-day moving average price is $25.98 and its 200 day moving average price is $26.83.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The firm's quarterly revenue was up 24.7% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PFE. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.